Following Complete Review of Phase 2 Trial Data Amgen Confirms Decision to Halt GDNF Study; Comprehensive Review of Scientific Findings, Patient Safety, Drove Decision.
Business Wire › February 11, 2005
Linked as:
Extract
Following Complete Review of Phase 2 Trial Data Amgen Confirms Decision to Halt GDNF Study; Comprehensive Review of Scientific Findings, Patient Safety, Drove Decision.
THOUSAND OAKS, Calif. -- Company Confirms Commitment to Parkinson's Disease Research
Citing patient safety concerns and scientific findings, Amgen Inc. (Nas...See the full content of this document
Sponsored links
